Blood Res.
2017 Dec;52(4):243-253. 10.5045/br.2017.52.4.243.
Brentuximab vedotin: clinical updates and practical guidance
- Affiliations
-
- 1Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea.
- 2Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. wskimsmc@skku.edu
- KMID: 2405060
- DOI: http://doi.org/10.5045/br.2017.52.4.243
Abstract
- Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. Owing to the remarkable efficacy shown in CD30-positive lymphomas, such as Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, BV was granted accelerated approval in 2011 by the US Food and Drug Administration. Thereafter, many large-scale trials in various situations have been performed, which led to extensions of the original indication. The aim of this review was to describe the latest updates on clinical trials of BV and the in-practice guidance for the use of BV.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- CD30＋ Large-Cell Transformation of Mycosis Fungoides Treated with Brentuximab Vedotin
- Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin
- Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer
- Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant‑eligible Korean patients with relapsed or refractory Hodgkin’s lymphoma
- A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
